A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV‐2 mediated inflammation to organ damage
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15328
Abstract: COVID‐19 has spread globally, affecting almost 160 million individuals. Elderly and pre‐existing patients (such as diabetes, heart disease and asthma) seem more susceptible to severe illness with COVID‐19. Roflumilast was licensed for usage in the… read more here.
Keywords: roflumilast exploring; exploring integrated; agent roflumilast; roflumilast ... See more keywords